



## ImmunoGen Announces Webcast of Presentation at Deutsche Bank's 43rd Annual Health Care Conference

May 2, 2018

WALTHAM, Mass.--(BUSINESS WIRE)--May 2, 2018-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Deutsche Bank 43<sup>rd</sup> Annual Health Care Conference. The presentation is scheduled for 8:40am ET on May 9, 2018.

A webcast of the presentation will be accessible live through the "Investors" section of the Company's website, [www.immunogen.com](http://www.immunogen.com); a replay will be available in the same location for approximately two weeks.

### About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FR<sup>+</sup>-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2 FORWARD II trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyła<sup>®</sup>, and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at [www.immunogen.com](http://www.immunogen.com).

Kadcyła<sup>®</sup> is a registered trademark of Genentech, a member of the Roche Group.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180502006049/en/>

Source: ImmunoGen, Inc.

### For Investors

ImmunoGen, Inc.  
Sarah Kiely, 781-895-0600  
[sarah.kiely@immunogen.com](mailto:sarah.kiely@immunogen.com)

or

### For Media

ImmunoGen, Inc.  
Courtney O'Konek, 781-895-0158  
[courtney.okonek@immunogen.com](mailto:courtney.okonek@immunogen.com)

or

FTI Consulting, Inc.  
Robert Stanislaro, 212-850-5657  
[robert.stanislaro@fticonsulting.com](mailto:robert.stanislaro@fticonsulting.com)